Atlas Venture Invests $5M in Q32 Bio's Private Placement, Maintains 11.5% Stake
QTTB has more than doubled off its 52-week low of $1.345 on elevated volume (1.9× avg).
Summary
Atlas Venture, a major institutional investor, purchased $5 million worth of common stock in Q32 Bio's recent private placement, increasing its total beneficial ownership to 11.5%.
Key Events · Ownership and Investor Activity · QTTB
-
Institutional Investment in PIPE
Atlas Venture Opportunity Fund III, L.P. purchased 625,000 shares of common stock at $8.00 per share in a private placement, totaling $5 million. This transaction closed on May 28, 2026.
-
Significant Ownership Stake
Collectively, the Atlas Venture reporting persons now beneficially own 2,717,106 shares, representing an estimated 11.5% of Q32 Bio's outstanding common stock.
-
Registration Rights Agreement
Q32 Bio entered into a registration rights agreement, requiring it to file a registration statement for the resale of shares and warrants issued in the private placement.
Analysis · QTTB · Life Sciences
Atlas Venture's $5 million investment in Q32 Bio's recent private placement demonstrates continued institutional confidence in the company. This investment, part of the larger $55 million PIPE announced yesterday, helps secure critical funding for the life sciences company.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1725 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $10.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $174.8M. The 52-week trading range was $1.35 to $13.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.